Therapeutics News

Twenty-six weeks of treatment with adalimumab was associated with improvements in a number of fingernail psoriasis outcomes compared with placebo, according to recent study findings.

Immunopulse IL-12 monotherapy and in combination with pembrolizumab was associated with encouraging response rates and safety data in patients with melanoma who may not respond to anti-PD-1 therapy, according to a press release.

A monthly schedule of platelet-rich plasma injections was safe and efficacious in patients with androgenetic alopecia and may be preferable to injections administered every three months, according to findings presented at the American Society for Dermatologic Surgery Annual Meeting.

Patients with moderate-to-severe plaque psoriasis experienced a durable response to Taltz through 108 weeks, according to results of the UNCOVER-3 trial.

Biosimilars remain an unfamiliar and oftentimes controversial topic among physicians in the U.S. Unanswered questions surrounding both the scientific and legislative issues associated with their introduction have left many physicians in the dark.

Adult patients with moderate to severe atopic dermatitis demonstrated improvements in overall disease severity after treatment with Dupixent, according to findings from the CAFÉ trial presented at the European Academy of Dermatology and Venereology Congress.

At 100 weeks, more than 80% of patients with moderate to severe plaque psoriasis showed improvement after treatment with guselkumab, according to findings presented at the 26th European Academy of Dermatology and Venereology Congress.

A biosimilar of adalimumab was associated with similar safety and efficacy outcomes compared with Humira in a cohort of patients with chronic plaque psoriasis, according to a company-issued press release.

Patients with moderate-to-severe atopic dermatitis experienced improvements in both clinical and patient-reported outcomes after treatment with Olumiant plus topical corticosteroids when compared with topical corticosteroids alone, according to phase 2 study data presented at the European Academy of Dermatology and Venereology Annual Congress in Geneva.

One patient in a large cohort of individuals with autoimmune blistering diseases developed pneumocystis pneumonia, suggesting that routine prophylaxis of this condition may not be warranted in this patient population, according to recent findings.